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INTRODUCTION
We previously reported the case of a diabetic patient with an-
giographically documented foveal avascular zone (FAZ) en-
largement after intravitreal bevacizumab following vitrectomy 
and intravitreal bevacizumab (Avastin; Genentech, San Fran-
cisco, CA, USA).1 We also reported that macular ischemia may 
have a negative effect on visual outcomes after intravitreal 
bevacizumab injection, both in macular edema secondary to 
branch retinal vein occlusion and in diabetic macular ede-
ma.2,3 Intravitreal bevacizumab may be safe for choroidal neo-
vascularization secondary to age-related macular degenera-
tion or myopia, because of normal retinal vascular circulation. 
However, intravitreal bevacizumab may develop or worsen 
pre-existing retinal ischemia when retinal vascular disorders 
exist. The present report describes a case of angiographically 
documented FAZ enlargement following a single intravitreal 
injection of bevacizumab for macular edema secondary to 
central retinal vein occlusion (CRVO).
CASE REPORT
Informed consent was obtained from the patient after expla-
nation of the nature and possible consequences of the study; 
the study protocol followed the tenets of the Declaration of 
Helsinki. A 71-year-old female who had typical fundus and 
angiographical change of CRVO with macular edema was 
treated with a single intravitreal injection of bevacizumab (Fig. 
1A and C). There were no complications related to intravitreal 
injections, such as intraocular pressure elevation or infection, 
and no abrupt changes on fundus examination at immediate 
follow up and 1 day and 7 days after injection. One month lat-
er, despite successful resolution of macular edema confirmed 
by optical coherence tomography, the patient complained of 
an acute decrease in vision that developed over a few days af-
ter the injection. Her best-corrected visual acuity was 20/40 at 
the time of injection and 20/50 at 1 week after injection. How-
ever, it had decreased to 20/1000 (Snellen equivalent) by one 
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month after injection. Postinjection fluorescein angiography 
images were taken to evaluate the retinal perfusion status. The 
FAZ area, which was calculated by manual outlining using the 
Heidelberg Eye Explorer program (Spectralis optical coher-
ence tomography, version 1.5.12.0; Heidelberg Engineering, 
Heidelberg, Germany), revealed an increase in FAZ area from 
0.37 mm2 to 3.11 mm2 (8.4-fold increase) (Fig. 1B and D). We 
put Avastin on hold and followed up on the patient without any 
treatment. After 1 month, the macular ischemia and cotton 
wool spots seemed to have been resolved.
DISCUSSION
Anti-vascular endothelial growth factor (VEGF) agents are 
safe and effective treatments for patients with macular edema 
secondary to CRVO,4 and have become the first-line treatment 
for many other retinal diseases. Campochiaro, et al.5 reported 
that treatment with ranibizumab (Lucentis; Genentech, South 
San Francisco, CA, USA) did not worsen retinal nonperfusion 
in patients with retinal vein occlusion, but rather reduced its 
occurrence, and that timely, aggressive blockade of VEGF pre-
vented the worsening of retinal nonperfusion, by promoting 
reperfusion. In addition, a previous study using fluorescein an-
giography reported no evidence of increasing retinal ischemia 
after intravitreal bevacizumab injections.6 
Nevertheless, the systemic use of bevacizumab in cancer 
chemotherapy has been found to be related to an increased risk 
of cardiovascular ischemia, and the use of bevacizumab is 
known to increase the risk of cerebrovascular events, including 
central nervous system (CNS) ischemic events and CNS hem-





Fig. 1. Fundus photography and fluorescein angiography, before (A and C) and one month after intravitreal bevacizumab injection (B and D). The macular 
edema resolved after a single intravitreal injection of 1.25 mg of bevacizumab. However, the foveal avascular zone area increased from 0.37 mm2 to 3.11 
mm2, and best-corrected visual acuity decreased from 20/40 to 20/1000 (Snellen equivalent).
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in metastatic carcinoma patients treated with bevacizumab.8 
Intravitreal bevacizumab may develop or even worsen pre-
existing retinal ischemia, by blocking physiological VEGF, 
which is essential for maintaining retinal circulation when 
retinal vascular disorders exist. A nonselective anti-VEGF an-
tibody, such as bevacizumab, not only blocks pathological 
VEGF, but also physiological VEGF, which is essential for 
maintaining foveal circulation. VEGF promotes endothelial 
cell proliferation and stimulates endothelial cell survival.9 
Moreover, VEGF enhances endothelial nitric oxide (NO) syn-
thase activity and upregulates the message and protein levels 
of the VEGF receptor in human endothelial cells. Thus, inhibi-
tion of VEGF could weaken the regenerative capacity of endo-
thelial cells, leading to thrombosis or hemorrhage.10 In addi-
tion, NO inhibition and VEGF blockade can result in several 
common complications, such as endothelial dysfunction or 
vascular occlusive events. Endothelial dysfunction disturbs ho-
meostatic balance, thereby prompting vasoconstriction of ves-
sel walls, platelet activation, leukocyte adherence, thrombosis, 
impaired coagulation, vascular inflammation, and atheroscle-
rosis.10 Leukocyte recruitment and adherence may also cause 
blockage of capillaries, resulting in capillary occlusion, which 
may account for bevacizumab-induced retinal ischemia when 
it is administered intravitreously. 
While intravitreal anti-VEGF is effective and should be con-
sidered as a first-line treatment for macular edema secondary 
to CRVO, it may lead to or aggravate macular ischemia. One 
should be aware of these possible complications during intra-
vitreal anti-VEGF administration. Further studies using serial 
optical coherence tomography angiography should prove 
helpful in determining whether anti-VEGF exacerbates macu-
lar ischemia in retinal vessel disorders.
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